Lupin achieves S&P Global ESG score of 91

This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth

Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg

Dexlansoprazole delayed-release capsules are a proton pump inhibitor

UK MHRA finds gut microbiome research unreliable across labs

False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample

LANXESS set to showcase cutting-edge infection control solutions

LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions

Enzymit and Cosun chart breakthrough in cell-free hyaluronic acid production

Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering

Lupin receives EIR from FDA for its Aurangabad facility

The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.

Lupin Manufacturing Solutions unveils dedicated oncology block at Vizag

Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities

The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million

FDA grants Orphan Drug Designation for Tinostamustine in malignant glioma

Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition

CereCore joins oracle partner network to strengthen healthcare IT and EHR services

The partnership aligns with the launch of Oracle Health’s next-generation electronic health record